Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
OPA1-03166 detects human phospho-c-Met (pTyr1003) from human samples.
OPA1-03166 has been successfully used in Western blot procedures. By Western blot, this antibody detects two bands between ~135 and ~150 kDa protein representing phospho-c-Met (pTyr1003) precursor and proteolytically cleaved forms.
OPA1-03166 immunizing phosphopeptide was derived from a region of human c-Met that contains tyrosine 1003. This sequence is 100% conserved in mouse and rat c-Met.
MET (cMET) is a receptor-like tyrosine kinase whose dysregulation has been linked to many types of human malignancies. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast; therefore, making it a target for cancer therapeutics and diagnostic testing.
仅用于科研。不用于诊断过程。未经明确授权不得转售。